Recently, Peng Liubao’s team from The Second Xiangya Hospital of Central South University, has published on the website ofJAMA Oncology(IF=20.871) an original research paper on pharmacoeconomics in oncology, entitledFirst-Line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma: A Cost-effectiveness Analysis. Dr. Wan Xiaomin is the first author, Professor Peng Liubao is the corresponding author, and the Second Xiangya Hospital of Central South University is the sole author’s unit.
This work is a pharmacoeconomic study of the treatment of advanced renal cell carcinoma with nivolumab combined with ipilimumab, and its research methods and results provide an approach and decision-making basis for promotion of safe, effective and economic clinical medication, and for formulation of medical and health policies.
Professor Peng Liubao’s team has long engaged in the study of pharmacoeconomics. In recent years it has four projects funded by Natural Science Foundation of China and has published more than 100 academic papers, including SCI papers, in this field. This research paper is another innovative achievement of his team after publication of research findings in the domain of pharmacoeconomics in such international authoritative journals asCancer(IF: 6.537) andPharmacoEconomics(IF: 4.011).
Pharmacoeconomics is a comprehensive applied discipline that integrates multiple disciplines such as clinical medicine, pharmacy, health economics, evidence-based medicine, and health outcome research and epidemiology, and studies the input and output of drug therapy from the aspects of clinical curative effects, adverse reactions, medical expenses in a comprehensively way. It aims to provide preferred solutions required for decision-making through systematic and scientific study of the cost input and health output of clinical drug therapy so as to maximum the limited social medical and health care resources.
JAMA Oncology, a sub-journal of oncology affiliated to JAMA, ranks the eighth in 223 oncology journals in the world. It has been listed in the “Top 0.5%” journals in the comprehensive ranking of journals of various disciplines worldwide, one of the most influential top-level journals in the field of oncology.
Source: The Second Xiangya Hospital of Central South University
